Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1305-1322

  Owens, Michael J ^a   Morgan, W Neal ^a   Plott, Susan J ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE RECEPTOR; HYDROXYNEFAZODONE; IMIPRAMINE; MUSCARINIC RECEPTOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORFLUOXETINE; NORSERTRALINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SERTRALINE; TRAZODONE; TRIAZOLE DERIVATIVE; VENLAFAXINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DEPRESSION; DRUG METABOLISM; DRUG RECEPTOR BINDING; GUINEA PIG; HUMAN; HUMAN CELL; NEUROTRANSMISSION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GUINEA PIGS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; TRIAZOLES;

EID: 0031456987     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. BARKER, E. L. AND BLAKELY, R. D.: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol. Pharmacol. 50: 957-965, 1996.
2. BARKER, E. L., KIMMEL, H. L. AND BLAKELY, R. D.: Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol. Pharmacol. 46: 799-807, 1994.
3. BOLDEN-WATSON, C. AND RICHELSON, E.: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52: 1023-1029, 1993.
4. BRANN, M. R., JØRGENSEN, H. B., BURSTEIN, E. S., SPALDING, T. A., ELLIS, J., PENELOPE-JONES, S. V. AND HILL-EUBANKS, D.: Studies of the pharmacology, localization, and structure of muscarinic acetylcholine receptors. Ann. NY Acad. Sci. 707: 225-236, 1993.
5. 3H]-mepyramine binding of brain membranes. J. Neurochem. 32: 1653-1663, 1979.
6. 3H]-5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 32: 737-743, 1993.
7. 3H]-yohimbine binding to rat cerebral and human platelet membranes, possible heterogeneity of α-adrenoceptors. Eur. J. Pharmacol. 84: 79-85, 1982.
8. CUSACK, B., NELSON, A. AND RICHELSON, E.: Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology 114: 559-565, 1994.
9. 3H]-imipramine. J. Pharmacol. Exp. Ther. 242: 364-371, 1987.
10. 1A-mediated serotonergic neurotransmission. CNS Drugs 4: suppl. 1, 29-38, 1995.
11. DE LEAN, A., HANCOCK, A. A. AND LEFKOWITZ, R. J.: Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 21: 5-16, 1982.
12. DÖRJE, F., WESS, J., LAMBRECHT, G., TACKE, R., MUTSCHLER, E. AND BRANN, M. R.: Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256: 727-733, 1991.
13. FONTAINE, R., ONTIVEROS, A., KENSLER, E. R., ROBERTS, D. L., KAPLITA, S., ECKER, J. A. AND FALUDI, G. A.: A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J. Clin. Psychiatry 55: 234-241, 1994.
14. FRANC, J. E., DUNCAN, G. F. FARMEN, R. H. AND PITTMAN, K. A.: High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J. Chromatogr. Biomed. Appl. 570: 129-138, 1991.
15. GALLI, A., DEFELICE, L. J., DUKE, B.-J., MOORE, K. M. AND BLAKELY, R. D.: Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J. Exp. Biol. 198: 2197-2212, 1995.
16. 3H]-8-hydroxy-2-)di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J. Neurochem. 44: 1685-1696, 1985.
17. HALL, M. D., GOZLAN, H., EMERIT, M. B., MESTIKAWY, S. EL., PICHAT, L. AND HAMON, M.: Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physio-chemical parameters and modifying agents. Neurochem. Res. 11: 891-912, 1986.
18. HEMRICK-LEUCKE, S. K., SNADDY, H. D. AND FULLER, R. W.: Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55: 479-483, 1994.
19. HILL, S. J.: Distribution, Properties, and functional characteristics of three classes of histamine receptor. Pharmacol. Rev. 42: 45-83, 1990.
20. 1-receptors in the brain of the guinea pig and the rat: differences in ligand binding properties and regional distribution. Br. J. Pharmacol. 68: 687-696, 1980.
21. KAUL, S., SHUKLA, U. AND BARBHAIYAA, R. H.: Pharmacokinetics of nefazodone after 50, 100 and 200 nig single and multiple oral doses. J. Clin. Pharmacol. 35: 830-839, 1995.
22. MAYOL, R. F., COLE, C. A., LUKE, G. M., COLSON, K. L. AND KEARNS, E. H.: Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Dispos. 22: 304-311, 1994.
23. 2 receptors in rat brain. Neuropsychopharmacology 2: 81-87, 1989.
24. MORGAN, W. N., OWENS, M. J., DALEY, J. T., KNIGHT, D. L., STOWE, Z. N. AND NEMEROFF, C. B.: The effects of reduced pH during serial dilutions in radio-ligand binding studies. Soc. Neurosci. Abstr. 21: 547.12, 1995.
25. MUNSON, P. J. AND RODBARD, D,: LIGAND: A versatile computerized approach for characterization of ligand binding systems. Anal. Biochem. 107: 220-239, 1980.
26. MUTH, E. A., HASKINS, J. T., MOYER, J. A., HUSBANDS, G. E. M., NIELSEN, S. T. AND SIGG, E. B.: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35: 4493-4497, 1986.
27. OWENS, M. J., KNIGHT, D. L., RITCHIE, J. C. AND NEMEROFF, C. B.: The 5-hydroxytryptamine agonist, (±)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration. J. Pharmacol. Exp. Ther. 256: 795-800, 1991.
28. OWENS, M. J., IENI, J. R., KNIGHT, D. L., WINDERS, K. AND NEMEROFF, C. B.: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 57: PL373-PL380, 1995.
29. 2A receptor binding after chronic hypercorticosteronemia, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. J. Pharmacol. Exp. Ther. 278: 1040-1049, 1996.
30. PACHOLCZYK, T., BLAKEY, R. D. AND AMARA, S. G.: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-354, 1991.
31. 3H]-Citalopram binding to brain and platelet membranes of human and rat. J. Neurochem. 56: 248-252, 1991.
32. QIAN, Y., GALLI, R., RAMAMOORTHY, S., RISSO, S., DEFELICE, L. J. AND BLAKKLY, R. D.: Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J. Neurosci. 17: 45-57, 1997.
33. RICHELSON, E. AND NELSON, A.: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J. Pharmacol. Exp. Ther. 230: 94-102, 1984.
34. RICKELS, K., SCHWEIZER, E., CLARY, C., FOX, I. AND WEISE, C.: Nefazodone and imipramine in major depression: a placebo-controlled trial. Br. J. Psychiatry 164: 802-805, 1994.
35. ROBINSON, D. S., MARCUS, R. N., ARCHIBALD, D. G. AND HARDY, S. A.: Therapeutic dose range of nefazodone in the treatment of major depression. J. Clin. Psychiatry 57: suppl. 2, 6-9, 1996.
36. RUFFOLO, R. R., JR., NICHOLS, A. J., STADEL, J. M. AND HIEBLE, J. P.: Structure and function of α-adrenoceptor. Pharmacol. Rev. 43: 475-505, 1991.
37. SEEMAN, P.: Receptor Tables, vol. 2: Drug Dissociation Constants For Neuroreceptors and Transporters, SZ Research, Toronto, 1993.
38. SPROUSE, J., CLARKE, T., REYNOLDS, L., HEYM, J. AND ROLLEMA, H.: Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 14: 225-231, 1996.
39. STANTON, T., BOLDEN-WATSON, C., CUSACK, B. AND RICHELSON, E.: Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 45: 2352-2354, 1993.
40. 3H]-rauwolscine. Life Sci. 33: 1105-1112, 1983.
41. TAYLOR, D. P., CARTER, R. B., EISON, A. S., MULLINS, U. L., SMITH, H., L., TORRENTE, J. R., WRIGHT, R. N. AND YOCCA, F. D.: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56: suppl. 6, 3-11, 1995.
42. 3H]-Nisoxetine: A radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J. Pharmacol. Exp. Ther. 260: 427-436, 1992.
43. 2 receptors of normal human brain in vitro. Eur. J. Pharmacol. 132: 115-121, 1986.